GI CONNECT has summarised the highlights of ASCO GI 2017 for you.
Cancers of the lower GI tract by Ass. Prof. Joleen Hubbard
GI CONNECT has summarised the highlights of ASCO GI 2017 for you.
Cancers of the lower GI tract by Ass. Prof. Joleen Hubbard
Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota. She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network.
Advisory boards: Bayer, Merck, BeiGene, Incyte
Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche
10 years of independent medical education in GI oncology
Journey through a patient case from testing and diagnosis to treatment and AE management
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Maximising outcomes for patients with advanced CRC
Make decisions for your patient at two key stages in their journey